Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Strong looking daily candle. Limited shares to go round think the MMS having to take this slow and steady to get max earnings for themselves. Hence the trading being over a few days. Providing we see a strong finish I think even more to come tomorrow. Just like previous big rises.
Personally I’ve forgotten about SC. For me the real asset is getting the glad free product to market. That will make a difference in clinical practice and provide IQAI a rosey future. What ever you think about SC it’s not the jewel in the crown.
Just looked online at the average wait time for patent to come through and seems it’s around 2-3 years. So October marks the 2nd year since application in then it could come through anytime from now on. Would be amazing for a double RNS SC sale and Gad free patent. I know that wishful thinking thou. GLA.
They should never sell. Potential is huge but if declined risk a difficult path to maximise the true potential over the years. Look at the bank of ceasars got trumps name all over it. Lots of history between them and him. Minimum £4 to even think about an offer. 272 an insult.
Thanks dark horse.
I tried looking but can’t find the results date. Was it the 28th sept? Seem to remember reading it referenced in one of the RNS ‘s . ? Can anyone else remember. If it is handy the webinar is the following day.
“Further details will be provided at the time of Full Year Results for the period ended 31 December 2019 and Interim Results for the six-month period ended 30 June 2020 expected to be issued on Monday, 28 September 2020.”
Therefore not long to wait.
“More recently, the IB product portfolio was made accessible via the Arterys AI marketplace. Arterys is an international company that offers a leading web-based (cloud), AI-powered platform on which the entire IB product line is available for trial or purchase. Training on the technology and clinical application for US sales and marketing teams was recently completed, and Arterys has started presenting IB solutions to prospective clients.”
No RNS needed but market waking up to it as not factored in till today.
Also worth adding, as said before on here, it’s not just about stone checker. If those figures are not a million miles off then an SP of 10-20p is easily possible.
Providing the deal is done then it really paves the way for IQAI to get its other products out there and creating value for the company and us.
Personally I like the sound of “IB CAD” potential to have a massive impact for clinicians and patients and of course us shareholders.
I just done a Bit of research maybe way off but could be logical.
so software packages can cost between $15k to $100k depending on the anatomical regions. As this is cutting edge software you could take the higher end for the retail cost of the software.
Cost of new ct scanners can be in the range of $1.3-2million dollars for 256 slice ct scanners. I presume for kidney stone scanning you would want the high slice scanners.
Major manufacturers of ct scanners are GE, Siemens, toshiba, and Phillips. So these are the likely candidates.
An estimate of total ct scanners worldwide is 30000. But not all of those would need the specific software on offer.
Let’s say just 5% of scanners can or chose to upgrade to the new software. 1500 x 100k = $150million. And say we get just 10% royalty for each sale. That’s $15million just on royalties. Plus upfront payment.
Make what you can of any of the info. Remember I could be way off but my attempt. Thought I’d try to put some decent conversation on heat other than slating each other.
GLA.
Well I’m in for a few more. My average now 109. Can only see an improvement on the last set of figures / trading update. Hopefully in all areas online retail and US. GLA
Surely this deserves an uptick to the high 70’s. Even if we calculate the sp on only payments received. 46% of previous SP takes it to above the 80’s. If it doesnt move at all the only thing to get it going again will be starting the dividend again.